相关实验视频

Updated: Jun 18, 2025

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood

Published on: October 12, 2012

使用新型肝素中和盒进行TEG® 6s凝血测试:技术验证和确定正常参考范围

Jan Hartmann¹, Joao Dias¹, Alexandra Shilo¹

¹Global Medical Office, Haemonetics Corporation, Boston, MA, US.

American journal of clinical pathology

|July 29, 2024

概括

这项研究确定了新型TEG 6s全球静血盒的正常参考范围. 这些发现验证了在临床环境中准确的血液静止测试的盒子.

科学领域:

血液静止和血栓形成研究.
在临床病理学中开发新型诊断工具.

背景情况:

准确的血液静止测试对于患者的护理至关重要.
TEG 6s 全球血静卡是一个用于评估血液凝固的新设备.

研究的目的:

为了确定TEG 6s全球静血盒的正常参考范围 (NRR).
为了验证新型TEG 6s弹用于血液静止评估的性能.

主要方法:

一个单臂研究,涉及健康的成年志愿者.
通过使用TEG 6s弹与各种测定分析了全血样本.
主要终点包括来自酸考林 (CK),CK与肝激酶 (CKH),RapidTEG与肝激酶 (CRTH) 和功能性纤维素与肝激酶 (CFFH) 试验的TEG参数.

主要成果:

为多个TEG参数建立NRR,包括在不同测定中最大幅度和反应时间.
功能性纤维激素测定 (CFFH-MA) 显示与克劳斯纤维激素度 (r=0.74) 有很强的相关性.
卡显示了可接受的性能与高纤维素生成性样本和验证的氨酸中和到特定度.

结论:

成功确定了TEG 6s 全球静血盒的正常参考范围.
这项研究作为概念验证,证明了使用这种新弹获得的结果的有效性和可靠性.

关键词:

凝血是凝固的过程.血液学血液学血液学质量质量质量质量质量质量.

更多相关视频

Leveraging Turbidity and Thromboelastography for Complementary Clot Characterization

Leveraging Turbidity and Thromboelastography for Complementary Clot Characterization

Published on: June 4, 2020

In Vitro Thrombosis Test for Ventricular Assist Devices

In Vitro Thrombosis Test for Ventricular Assist Devices

Published on: March 21, 2025

相关概念视频

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...